Nutrien Ltd. Q2 FY26 Earnings Analysis

Published 29 May 2026 | Chemicals | Market Cap: ₹33.6K Cr

Price

69.65

Market Cap

₹33.6K Cr

P/E Ratio

14.2

Revenue Rank

Rank 3

Margin Rank

Rank 3

Earnings Summary

- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence.

📊 Revenue & Sales Performance

Rank 3

- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Strong global demand supports sustaining or increasing sales, with potash shipments forecasted between 74 to 77 million tonnes, indicating potential growth beyond last year's 74.5 million tonnes. - High single-digit growth anticipated in proprietary products gross margin, driven by new product launches and expansion in core retail geographies including the U.S., Australia, and international markets. - Retail business remains constructive with maintained EBITDA guidance of $1.75 to $1.95 billion for 2026, supported by strong customer engagement and expanding proprietary products. - Growth is partly driven by crop nutrient replenishment needs following a large 2025 corn and soybean harvest and increased acres planted in key markets. - Ongoing strategic reviews and portfolio optimization, including potential sales in certain business segments, aim to strengthen core growth areas.

📈 Profitability & Margins

Rank 3

- Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence. - High single-digit growth expected in proprietary products gross margin in 2026 due to new product launches, increased demand, and international expansion. - No major changes anticipated in margin expectations across product segments except some pressure on phosphate margins in Q2 due to elevated input costs. - The company is constructive on potash demand and expects shipment range of 74-77 million tonnes in 2026, testing global logistics and production capacity. - Nitrogen segment benefits from higher global benchmarks and low-cost production, driving strong adjusted EBITDA. - Retail adjusted EBITDA guidance remains $1.75 billion to $1.95 billion with strong customer engagement during planting season. - Nutrien is focused on cost management, asset optimization, and capital allocation to sustain structural free cash flow growth and returns. - Overall, market conditions and strategic initiatives support positive earnings outlook and stable profitability for 2026.

🏗️ Capital Expenditure Plans

Yes

- **2026 Capital Expenditures Guidance:** Maintained at $2 billion to $2.1 billion. - **Strategic Reviews:** - Phosphate business: Completing detailed assessment of assets and configurations; progressing a sale process with significant initial expressions of interest. - Trinidad nitrogen operations: Evaluating all strategic options, including potential sale, focused on strengthening core North American assets. - Brazilian business: Reviewing components and commenced sales process for Brazilian soybean seed business, expected to complete in H2 2026. - **Capital Allocation:** Continuing share repurchases at approximately $55 million per month in Q2 2026. - **Investment Focus:** Simplifying the business, strengthening core asset base, improving capital efficiency to drive structural free cash flow growth and sustainable returns.

💰 Fundraising & Capital Structure

No information

- The company completed share repurchases of approximately $550 million last year and reduced adjusted net debt by approximately $600 million. - In 2026, they plan to continue share repurchases on a ratable basis with a pace of approximately $55 million per month so far in the second quarter. - They see opportunities to further strengthen the balance sheet in 2026. - There is no explicit mention of new fundraising through debt or equity during the call. - The focus remains on consistent capital allocation, optimizing the portfolio, and maintaining a strong balance sheet.

📋 Order Book & Pipeline

No information

The provided pages do not explicitly state current or expected orderbook or pending orders in numeric terms. However, relevant insights include: - Prior to the Middle East conflict, approximately 35% of second quarter planned nitrogen sales volumes were committed, similar to the prior year. - Canpotex (potash exporter) is fully committed through the end of June. - For nitrogen, sales volume guidance remains 9.2 to 9.7 million tonnes with planned turnarounds at 3 facilities in 2026. - Retail inventories are expected to be very empty towards the end of spring, indicating anticipated refill orders. - Strong customer engagement and product movement have been reported thus far into 2026. - Inventory remains short due to ongoing Middle East disruptions, impacting over 30% of global urea trade and 25% of ammonia and phosphate. - Market remains tight with supply-demand fundamentals expected to keep pricing and demand elevated near term. No exact numerical order backlog or pending order values provided.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

No information

Frequently Asked Questions

What were Nutrien Ltd. Q2 FY26 results?

- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence.

What is Nutrien Ltd. share price analysis?

Nutrien Ltd. currently shows a below-average growth signal. The stock trades at a P/E of 14.2 with a market cap of $33,569. Investors should review the full earnings analysis for detailed insights.

Is Nutrien Ltd. planning capital expenditure?

- **2026 Capital Expenditures Guidance:** Maintained at $2 billion to $2.1 billion.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.